Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

64.72USD
17 Aug 2018
Change (% chg)

$0.56 (+0.87%)
Prev Close
$64.16
Open
$64.24
Day's High
$64.91
Day's Low
$64.05
Volume
1,225,444
Avg. Vol
1,544,895
52-wk High
$65.89
52-wk Low
$48.58

Select another date:

Wed, Jul 18 2018

Photo

Abbott Labs raises 2018 earnings forecast, shares hit record high

Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions.

UPDATE 2-Abbott Labs raises 2018 earnings forecast, shares hit record high

* Shares hit record high (Adds details from conference call, analysts' quotes, updates shares)

Abbott Labs tops profit estimates, raises full-year earnings forecast

July 18 Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts' estimates, powered by higher sales across its businesses, including its top-earning medical device unit.

Allergan appoints former Abbott executive to its board

Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

Allergan appoints former Abbott executive to its board

June 14 Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

BRIEF-Abbott's Investigational Tendyne Device For Mitral Valve Replacement Demonstrates Positive Outcomes At 30 Days In Global Study

* ABBOTT'S INVESTIGATIONAL TENDYNE™ DEVICE FOR MITRAL VALVE REPLACEMENT DEMONSTRATES POSITIVE OUTCOMES AT 30 DAYS IN GLOBAL STUDY

BRIEF-5-Year Study Data Confirm Positive Outcomes For Patients When Abbott Diagnostic Tool Was Used To Guide Heart Stenting Decisions

* FIVE-YEAR STUDY DATA CONFIRM POSITIVE OUTCOMES FOR PATIENTS WHEN ABBOTT DIAGNOSTIC TOOL WAS USED TO GUIDE HEART STENTING DECISIONS Source text for Eikon: Further company coverage:

BRIEF-Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter

* ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO WITH FDA CLEARANCE OF ADVANCED MAPPING CATHETER

BRIEF-Abbott's Xience Sierra Heart Stent Receives National Reimbursement In Japan

* ABBOTT'S XIENCE SIERRA™ HEART STENT RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:

BRIEF-Abbott Laboratories Says Shareholders Rejected Proposal Requesting Board Of Directors Adopt Policy That Board Chairman Be Independent Director

* ABBOTT LABORATORIES SAYS SHAREHOLDERS REJECTED PROPOSAL REQUESTING CO'S BOARD OF DIRECTORS ADOPT POLICY THAT BOARD CHAIRMAN BE INDEPENDENT DIRECTOR Source text: (https://bit.ly/2KqCwQY) Further company coverage:

Select another date: